香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Mediwelcome Healthcare Management & Technology Inc. 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2159） 須予披露交易 對目標公司進行減資 減資決議案 於 2025 年 6 月 13 日 ， 北 京 麥 迪 康 健（ 本 集 團 的 中 國 經 營 實 體 之 一 ）、 孫 健 先 生 及 段麗麗女士（ 均為目標公司股東 ）通過減資決議案，據此，議決目標公司的註冊 資本將減少約人民幣3.1百萬元，佔目標公司現有註冊資本51.00 %，全部均從北 京麥迪康健所擁有的註冊資本中減少。 於本公告日期及減資事項完成前，目標公司為本公司間接非全資附屬公司，由 北京麥迪康健及現有股東分別持有約51.00 %及約49.00 % ...

環境、社會及管治報告 緒言 麥迪衛康健康醫療管理科技股份有限公司（「本公司」）及其附屬公司（統稱「本集團」或「我們」）根據香港聯合交 易所有限公司（「聯交所」）《證券上市規則》附錄C2《環境、社會及管治報告指引》（「環境、社會及管治指引」）所 載的適用要求，提呈此份環境、社會及管治報告（「環境、社會及管治報告」），本集團已遵守環境、社會及管治 指引所載的「不遵守就解釋」條文規定。 本集團將以數字化醫療平台為基礎，繼續探求開拓互聯網醫院業務及健康管理服務，從而構建創新的數字化醫 療業務模式。 憑藉真實世界的數據及自身涵蓋患者全旅程的經驗，本集團將進一步挖掘醫療健康行業中利益相關方的未盡 需求，以界定及打造涵蓋疾病預防及篩查、診斷與治療、康復及健康管理的全流程健康服務體系，當中將覆蓋 患者診前、診中、診後的多類創新健康管理工具、產品及個性化服務，包括但不限於基因檢測、疾病篩查、輔 助診療、數字化醫療、健康處方、疾病康復、醫生助理、企業客戶健康管理等。此外，本集團亦重點引進健康 技術人才，以及管理及營銷專才。結合本集團內外利益相關方的共同努力，並憑藉內在優勢，本集團預期將打 造一個創新型醫療健康生態體系。隨著經營業 ...

（於開曼群島註冊成立的有限公司） （股份代號：2159） （ 以下稱「公司」） 提名委員會 — 職權範圍 1. 成員 2. 秘書 3. 會議 – 1 – 1.1 公司的提名委員會（「提名委員會」）須由公司董事會（「董事會」）成立，且提名 委員會的大多數成員應為獨立非執行董事及至少一名性別不同的董事。提名 委員會成員須由董事會委任。 1.2 提名委員會之主席應由董事會委任，並須由董事會主席或提名委員會中之獨 立非執行董事擔任。 1.3 提名委員會成員的委任年期由董事會於委任時決定。 Mediwelcome Healthcare Management & Technology Inc. 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 2.1 提名委員會之秘書應由任何一位聯席公司秘書擔任。 2.2 提名委員會可不時委任其他任何具備合資格及經驗之人士為提名委員會之秘 書。 3.1 提名委員會成員可以在有需要的情況下於任何時間召開會議。 3.2 任何會議之通知最少須於該會議舉行前14天作出，除非提名委員會全體成員 一致通過豁免該通知。不論所作出之通知期，成員出席會議將被視為該成員 豁免所需之通知 ...

Dear Non-registered shareholder(s) (Note 1) , 28 April 2025 Mediwelcome Healthcare Management & Technology Inc. (the "Company") – Notice of Publication of 2024 Annual Report and Circular for Annual General Meeting ("Current Corporate Communications") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.mediwelcome.com (the "Company Website") and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hke ...

(Stock Code 股份代號: 2159) N O T I F I C AT I O N L E T T E R 通 知 信 函 Dear registered shareholder(s) (Note 1) Mediwelcome Healthcare Management & Technology Inc. 麥迪衛康健康醫療管理科技股份有限公司 ((Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） 各位股東 ( 附 註 1 )： 麥迪衛康健康醫療管理科技股份有限公司（「本公司」） —2024 年報、股東週年大會通函及委任表格（「本次公司通訊文件」）之刊發通知 28 April 2025 Mediwelcome Healthcare Management & Technology Inc. (the "Company") – Notice of Publication of 2024 Annual Report, Circular and Proxy Form for Annual General Me ...

Mediwelcome Healthcare Management & Technology Inc. 麥迪衛康健康醫療管理科技股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2159） 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 通 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 股 東 週 年 大 會 通 告 茲 通 告 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司（「本 公 司」）謹 訂 於2025年6月 25日（星 期 三）上 午 十 時 正 假 座 中 國 北 京 市 朝 陽 區 東 四 環 北 路2號 上 東 公 園 里 12樓1號 會 議 室 舉 行 股 東 週 年 大 會（「股 東 週 年 大 會」），以 處 理 下 列 事 項： 普 通 決 議 案 (B) 授 權 本 公 司 董 事 會 釐 定 其 各 自 的 董 事 薪 酬 ...

此 乃 要 件 請 即 處 理 閣 下 如 對 本 通 函 任 何 方 面 或 應 採 取 的 行 動 有 任 何 疑 問，應 諮 詢 閣 下 的 股 票 經 紀 或 其 他 註 冊 證 券 商、銀 行 經 理、律 師、專 業 會 計 師 或 其 他 專 業 顧 問。 閣 下 如 已 出 售 或 轉 讓 名 下 所 有 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 股 份，應 立 即 將 本 通 函 連 同 隨 附 的 代 表 委 任 表 格 送 交 買 主 或 承 讓 人、或 經 手 買 賣 或 轉 讓 的 銀 行、股 票 經 紀 或 其 他 代 理 商，以 便 轉 交 買 主 或 承 讓 人。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 通 函 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 通 函 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 ...

Financial Performance - Total revenue for 2024 was RMB 321,558,000, a decrease of approximately 2.3% compared to RMB 331,308,000 in 2023[6] - Gross profit increased to RMB 51,004,000 in 2024, up from RMB 29,895,000 in 2023, representing a growth of approximately 70.7%[6] - The group reported a revenue decrease of approximately 2.9%, from about RMB 331.3 million in the year ended December 31, 2023, to approximately RMB 321.6 million for the current year[24] - Revenue from medical conference services decreased by approximately 3.1% from about RMB 163.7 million to approximately RMB 158.7 million, attributed to reduced economic activity in China[25] - Overall gross profit increased by approximately RMB 21.1 million to about RMB 51.0 million, with gross profit margin rising from 9.0% to 15.9%[32] - Other income, gains, and losses decreased by approximately 47.8% to about RMB 3.8 million from approximately RMB 7.3 million, primarily due to reduced VAT refunds and fair value changes[33] - The company recorded a net loss of approximately RMB 46.9 million for the year, an improvement from a net loss of approximately RMB 96.1 million in the previous year[40] Assets and Liabilities - Total assets decreased to RMB 194,088,000 in 2024 from RMB 214,318,000 in 2023, a decline of about 9.4%[7] - Total liabilities increased to RMB 120,809,000 in 2024, up from RMB 94,351,000 in 2023, representing a rise of approximately 28%[7] - Trade receivables decreased from approximately RMB 56.9 million as of December 31, 2023, to approximately RMB 50.4 million as of December 31, 2024, due to more effective credit control measures and a decrease in sales[43] - Trade payables increased from approximately RMB 32.3 million as of December 31, 2023, to approximately RMB 37.6 million as of December 31, 2024, attributed to improved cash flow management[44] - Current assets net value decreased from approximately RMB 88.8 million as of December 31, 2023, to approximately RMB 43.8 million as of December 31, 2024[47] - Cash and bank balances decreased by approximately 10.8%, from RMB 80.4 million as of December 31, 2023, to RMB 71.7 million as of December 31, 2024[48] - Total bank loans increased from RMB 21.5 million as of December 31, 2023, to RMB 39.0 million as of December 31, 2024, resulting in a debt-to-equity ratio of 53.3%[49] Operational Metrics - The total number of registered doctors reached 53,926, an increase of about 6.6% compared to 2023[9] - The number of registered patients grew to 320,696, reflecting a growth of approximately 15.2% year-over-year[9] - Online consultations reached 429,122, marking an increase of approximately 24.7% from the previous year[9] - The total number of academic content produced reached 1,306,769, including various formats such as surveys and educational articles[16] - As of December 31, 2024, the number of registered doctors on the platform exceeded 747,873, with online education activities totaling 66,645 sessions for doctors and 27,631 for patients, achieving a total view count of 14,038,024[16] Strategic Initiatives - The company plans to enhance digital healthcare services by integrating AI and web 3.0 technologies, aiming for improved patient interaction and service efficiency[12] - The application of AIGC technology has significantly advanced, enhancing the functionality of multiple platforms within the company[14] - The group aims to enhance its business scale and expand partnerships with more hospitals and medical institutions globally by 2025[19] - The group plans to leverage AIGC technology to improve clinical applications and enhance digital medical communication solutions[22] - The group is focused on continuous innovation and expansion in digital healthcare services, particularly in personalized doctor-patient interactions[20] Governance and Compliance - The company has adopted corporate governance practices in accordance with the Hong Kong Stock Exchange's listing rules, ensuring transparency and accountability[64] - The board consists of effective leadership with a mix of executive and independent non-executive directors, ensuring diverse perspectives in decision-making[75] - The board is committed to high levels of corporate governance to protect shareholder interests and enhance corporate value[64] - The audit committee consists of three independent non-executive directors, ensuring compliance with the necessary professional qualifications[87] - The board has established three committees: the audit committee, remuneration committee, and nomination committee, each with specific written terms of reference[85] Human Resources - Employee costs for the year ended December 31, 2024, were approximately RMB 66.9 million, a decrease of about 30.7% from RMB 96.4 million for the year ended December 31, 2023[57] - The total number of senior management personnel with salaries ranging from RMB 1 to RMB 500,000 is 7, while those earning between RMB 500,001 and RMB 1,000,000 is 4[91] - The company emphasizes a fair compensation system and conducts annual performance evaluations for employees[177] Shareholder Communication - The company maintains effective communication with shareholders through various channels, including annual general meetings[141] - The company has established a shareholder communication policy to ensure timely and relevant information is provided to shareholders[146] - The company encourages electronic communication with shareholders to reduce environmental impact and improve information dissemination[147] Risk Management - The board is responsible for reviewing the effectiveness of risk management and internal control systems at least annually[119] - The audit committee assists the board in managing and supervising the design, implementation, and monitoring of risk management and internal control systems[120] - The company conducts regular internal control assessments to identify risks affecting business operations and compliance[122] Market Position and Client Relationships - The company provides three main services: medical conference services, patient education and self-testing services, and marketing strategy and consulting services[173] - As of December 31, 2024, major customers accounted for 28% of the company's trade receivables, with approximately 74% of trade receivables from major customers settled by the report date[179] - The company has established long-term relationships with major clients, with relationship durations ranging from 7 to 21 years[179]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 董事名單及其角色和職能 麥迪衛康健康醫療管理科技股份有限公司董事會（「董事會」）成員載列如下： Mediwelcome Healthcare Management & Technology Inc. 麥 迪 衛 康 健 康 醫 療 管 理 科 技 股 份 有 限 公 司 執行董事 施煒先生 （ 董事長 ） 楊為民先生 王亮先生 劉桂金女士 非執行董事 劉夏先生 獨立非執行董事 （於開曼群島註冊成立的有限公司） （股份代號：2159） 宋瑞霖先生 David Zheng Wang先生 楊曉曦先生 – 1 – | 董事會設立三個委員會。下表提供各董事會成員於該等委員會中所擔任的職位。 | | --- | | | 董事委員會 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 董事 | | | ...

Financial Performance - Total revenue for the year ended December 31, 2024, was RMB 321,558,000, a decrease of 2.26% compared to RMB 331,308,000 in 2023[3] - Gross profit for the same period was RMB 51,004,000, representing a significant increase of 70.5% from RMB 29,895,000 in 2023[3] - The company reported a net loss of RMB 46,947,000 for the year, an improvement from a net loss of RMB 96,091,000 in 2023[3] - Basic and diluted loss per share improved to RMB 23.63 from RMB 49.15 in the previous year[3] - The total comprehensive loss for the year was RMB 46,688,000, an improvement from RMB 80,192,000 in 2023[3] - The operating loss for the company was RMB 103,665,000 in 2024, compared to an operating loss of RMB 48,975,000 in 2023, indicating a significant increase in losses[17] - The company reported a net loss of RMB 45,245,000 for 2024, compared to a loss of RMB 94,096,000 in 2023, indicating a significant improvement in financial performance[30] Expenses and Cost Management - Research and development expenses decreased to RMB 18,680,000 from RMB 32,685,000, a reduction of 42.9%[3] - Selling and distribution expenses were reduced to RMB 20,666,000 from RMB 22,335,000, a decrease of 7.5%[3] - Administrative expenses decreased to RMB 39,924,000 from RMB 51,014,000, a reduction of 21.7%[3] - The total employee costs for 2024 amounted to RMB 66,845,000, down from RMB 96,425,000 in 2023, reflecting a decrease of about 30.7%[22] - Interest expenses related to lease liabilities decreased to RMB 546,000 in 2024 from RMB 732,000 in 2023, indicating improved cost management[21] - Financial costs totaled RMB 1,087,000 in 2024, a decrease from RMB 1,304,000 in 2023, reflecting better financial management[21] Assets and Liabilities - Total assets decreased from RMB 214,318,000 to RMB 194,088,000, a decline of approximately 9.4% year-over-year[4] - Total liabilities increased from RMB 92,271,000 to RMB 117,046,000, representing a rise of about 27% year-over-year[4] - Total equity decreased from RMB 119,967,000 to RMB 73,279,000, a significant drop of approximately 38.9% year-over-year[5] - The company reported a net asset value of RMB 43,814,000, down from RMB 88,798,000, a decrease of about 50.7% year-over-year[4] - The company's borrowings increased from RMB 21,507,000 to RMB 39,027,000, an increase of about 81.5% year-over-year[4] Revenue Breakdown - Revenue from medical conference services decreased by approximately 3.1% to about RMB 158.7 million, primarily due to reduced economic activity in China[47] - Revenue from marketing strategy and consulting services increased by approximately 0.2% to about RMB 137.1 million, driven by increased demand[48] - Revenue from digital marketing solutions decreased by approximately 4.1% to about RMB 10.1 million, attributed to a slowdown in demand[49] - Revenue from patient education and self-testing services increased by approximately 26.7% to about RMB 7.1 million, due to an expanded customer base and improved customer retention[50] - Revenue from CRO services decreased by approximately 53.9% to about RMB 5.4 million, due to reduced economic activity and a strategic focus on higher-margin projects[51] - Revenue from internet hospital services increased by approximately 4.9% to about RMB 3.2 million, driven by increased demand[52] Taxation and Financial Support - The effective corporate income tax rate for the group is 25%, with certain entities qualifying for a reduced rate of 15% as high-tech enterprises[25] - The group has maintained a 100% tax deduction for qualified R&D expenses for both years, ensuring continued financial support for innovation[26] - The company reported a deferred tax expense of RMB (1,108,000) for 2024, compared to a deferred tax benefit of RMB 1,776,000 in 2023[24] Digital Services and Technology - The company has implemented AI and web 3.0 technologies to enhance its digital services, significantly improving patient education and communication experiences[36] - The company has expanded its digital services to cover rare diseases, aiming to reach a broader patient demographic[38] - The company has introduced a new platform based on web 3.0 technology to assist physicians in managing digital assets and facilitate future copyright transactions[37] - The application of AIGC technology has significantly enhanced the functionality of various medical platforms, improving service efficiency across the industry[36] Future Plans and Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[18] - The company aims to further enhance its business scale by expanding collaborations with more hospitals and medical institutions globally in 2025[41] - The company plans to continue optimizing its digital healthcare service model and enhance personalized doctor-patient interaction capabilities[43] - The company will leverage AI technology and web 3.0 to explore innovative applications and enhance the precision of medical services and market digital services[43] Corporate Governance and Structure - The consolidated financial statements include the financial results of the company and its controlled entities, reflecting the group's control over subsidiaries[10] - The group will reassess control over subsidiaries if any of the control criteria change, impacting the consolidation of financial results[10] - The board of directors did not recommend any final dividend for the year ended December 31, 2024[91] - The company will publish its annual performance report for the year ending December 31, 2024, on the Hong Kong Stock Exchange website and its own website[96]